RE-Stem Biotech is a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers. Backed by state-of-the-art GMP facilities and an international team of world-leading scientists, doctors and directors, RE-Stem currently has a robust technology platform including three profitable therapies on the market and six additional therapies.
Incorporated and headquartered in 2012 in Suzhou, China, RE-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing, and Ganzhou and Kunming.